{
    "clinical_study": {
        "@rank": "156394", 
        "arm_group": [
            {
                "arm_group_label": "Insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics\n      (the effect of the investigated drug on the body) and pharmacokinetics (the exposure of the\n      trial drug in the body) of insulin degludec (insulin 454), an explorative formulation, not\n      similar to the proposed commercial formulation, with insulin glargine in subjects with type\n      1 and type 2 diabetes."
        }, 
        "brief_title": "Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes", 
        "completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Glycosylated haemoglobin (HbA1c) below or equal to 10 procent based on central\n             laboratory results\n\n          -  Specific inclusion criteria for subject with type 1 diabetes:\n\n          -  Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12\n             months prior to screening\n\n          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)\n\n          -  Specific inclusion criteria for subject with type 2 diabetes:\n\n          -  Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening\n\n          -  Treated with insulin for the past 3 months prior to screening\n\n          -  Body Mass Index (BMI) between 22.0 and 35.0 kg/ m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject with a history of significant multiple drug allergies or with a known allergy\n             or suspected allergy to the trial product or any medicine chemically related to the\n             trial product,as judged by the Investigator.\n\n          -  Subject with a history of or presence of cancer\n\n          -  Any condition that the Investigator and/or Sponsor feels would interfere with study\n\n          -  Specific exclusion criteria for subject with type 2 diabetes:\n\n          -  Therapy with oral antidiabetic drugs within the past 3 months prior to screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865292", 
            "org_study_id": "NN5401-1719", 
            "secondary_id": "2006-001915-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin degludec", 
                "description": "Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "description": "Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-Blind, Single Dose, Six-Period Cross-over Dose Response Trial Comparing the Pharmacodynamics and Pharmacokinetics of Insulin 454 With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the glucose infusion rate curve", 
            "safety_issue": "No", 
            "time_frame": "0-24 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the insulin degludec/insulin glargine curve", 
            "safety_issue": "No", 
            "time_frame": "0-96 hours after dosing"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}